CoChat

A prospective, claims‐based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

Open access
Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., Chan, K. A. · 2014 · Diabetes, Obesity and Metabolism
Cited by 81

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aim: We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post‐marketing safety assessment programme. Methods: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase‐4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates ( IR /100 000 person‐years), rate ratio ( RR ) and 95% confidence intervals ( CI ) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models. Results: The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non‐glucagon‐like peptide‐1 ( GLP ‐1)‐based therapies (adjusted RR 1.10; CI 0.81–1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non‐ GLP ‐1‐based therapies (adjusted RR 0.65; 95% CI 0.26–1.60). Conclusion: We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12230

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 81

Metadata

Authors
Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., & Chan, K. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-11-26
Volume
16
Issue
3
Pages
273-275
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2061738696
Cited by
81
References
5
FWCI
8.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.